TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39488138
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Vaginal laser and PFE)
Study: 39488216
Drug: Apremilast 30
Normalized name: apremilast 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 30 mg orally twice per day after a 5-day titration period
Study: 39488229
Drug: Integrated care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated care model (group Problem Management Plus and antidepressant therapy)
Study: 39488549
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for genomic high-risk tumors
Study: 39488549
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy for genomic high-risk tumors
Study: 39488549
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy for genomic low-risk tumors
Study: 39488549
Drug: No endocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No endocrine therapy for genomic low-risk tumors
Study: 39488682
Drug: Baseline insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baseline insulin
Study: 39488682
Drug: Baseline IRS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline IRS (Insulin×0.0295 + C-peptide×0.00372)
Study: 39488821
Drug: IcoSema (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: IcoSema (175 U icodec, 0.5 mg semaglutide)
Study: 39488821
Drug: Semaglutide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide (0.5 mg)
Study: 39488825
Drug: Berberine; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine; specific dosage and duration not mentioned
Study: 39489399
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment control arm with no intervention during the main study period.
Study: 39489541
Drug: OncoPrism-HNSCC assay
Approvals — FDA: no, EMA: no, PMDA: no
Description: OncoPrism-HNSCC assay in monotherapy cohort (n=62)
Study: 39489541
Drug: OncoPrism-HNSCC assay
Approvals — FDA: no, EMA: no, PMDA: no
Description: OncoPrism-HNSCC assay in chemo-immunotherapy cohort (n=50)
Study: 39489895
Drug: Nintedanib 150
Normalized name: nintedanib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 150 mg orally twice per day (possible reduction to 100 mg twice per day in case of side-effects or hepatotoxicity) for 12 months.
Study: 39489924
Drug: Intensified alkylating
Normalized name: petroleum alkylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified alkylating chemotherapy (IACT)
Study: 39489924
Drug: Conventional-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose chemotherapy (CDCT)
Study: 39490969
Drug: Serum antiglycopeptidolipid
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum antiglycopeptidolipid core IgA antibody test
Study: 39490985
Drug: Hypotension-avoidance strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotension-avoidance strategy (target intraoperative MAP 80 mm Hg or over, hold renin-angiotensin-aldosterone system inhibitors on day of surgery and for two days after)
Study: 39490985
Drug: Hypertension-avoidance strategy
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertension-avoidance strategy (target intraoperative MAP 60 mm Hg or more, continue all antihypertensives before and after surgery)
Study: 39491310
Drug: ERT16 (16-session
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERT16 (16-session emotion regulation therapy)
Study: 39491310
Drug: ERT8 (8-session
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERT8 (8-session emotion regulation therapy)
Study: 39491396
Drug: Darolutamide 600
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darolutamide 600 mg twice daily (adjusted for crossover)
Study: 39491599
Drug: Phage therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phage therapy (172 pharmaceutical phage cocktails targeting Staphylococcus aureus and/or Pseudomonas aeruginosa; 57 for local injection and 99 for intravenous injection)
Study: 39491599
Drug: Phage therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phage therapy
Study: 39491902
Drug: Transcranial focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial focused ultrasound (tfUS) targeting the right amygdala, 10-min sessions, 8 weekly sessions
Study: 39491945
Drug: Midazolam nasal
Normalized name: midazolam Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam nasal spray (MDZ-NS) 5 mg administered for seizure clusters, with a second 5 mg dose possible if seizures did not terminate within 10 min or recurred within 10 min-6 h.
Study: 39492363
Drug: Intravascular lithotripsy
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular lithotripsy (IVL) as adjunctive treatment in coronary angioplasty
Study: 39492701
Drug: Tailored antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored antiplatelet therapy (early escalation with low-dose ticagrelor at 60 mg twice daily plus aspirin for <6 months, followed by late de-escalation to clopidogrel monotherapy for >6 months)
Study: 39492701
Drug: Standard dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dual antiplatelet therapy (DAPT) with clopidogrel plus aspirin for 12 months
Study: 39492841
Drug: cadonilimab at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: cadonilimab at a dosage of 6 mg/kg on day 1 of each 21-day cycle combined with intravenous liposomal irinotecan at a dosage of 70 mg/m2
Study: 39493359
Drug: Smartwatch +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartwatch + cardiac patch monitor
Study: 39493359
Drug: Cardiac patch
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac patch monitor only
Study: 39493729
Drug: Frequent error
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Frequent error augmentation physical therapy (F-EA-PT)
Study: 39493729
Drug: Standard-of-care physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care physical therapy (SOC-PT)
Study: 39493888
Drug: guselkumab (100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab (100 mg every 4 weeks (Q4W) or at Weeks 0, 4, and then Q8W)
Study: 39494607
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron replacement therapy (IRT) with probiotics, specific dosage and duration not mentioned.
Study: 39494607
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron replacement therapy (IRT) without probiotics, specific dosage and duration not mentioned.
Study: 39495140
Drug: ECC5004 (1-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECC5004 (1-300 mg single doses in healthy volunteers; 5, 10, 30, and 50 mg multiple daily doses in patients with T2DM for 28 days)
Study: 39495243
Drug: Inappropriate DOAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate DOAC dosing
Study: 39666256
Drug: Appropriate DOAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate DOAC dosing
Study: 39495467
Drug: Mitiperstat 10
Normalized name: Mitiperstat
DrugBank: Mitiperstat (DB18963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitiperstat 10 mg
Study: 39495467
Drug: Mitiperstat (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitiperstat (all doses)
Study: 39495531
Drug: Deferiprone 15
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone 15 mg/kg twice a day
Study: 39495965
Drug: Survodutide (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survodutide (3.6 or 6.0 mg, once-weekly subcutaneous injections)
Study: 39495965
Drug: Placebo (once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once-weekly subcutaneous injections)
Study: 39496199
Drug: Experimental lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental lozenges containing laccase enzyme and green coffee extract (with flavor)
Study: 39496199
Drug: Experimental lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental lozenges containing laccase enzyme and green coffee extract (without flavor)
Study: 39497332
Drug: Low-dose cone-beam
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cone-beam computed tomography (CBCT) protocol
Study: 39497332
Drug: Standard-dose cone-beam
Normalized name: Pinus strobus cone extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose cone-beam computed tomography (CBCT) protocol
Study: 39497751
Drug: Crizanlizumab 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizanlizumab 5.0 mg/kg
Study: 39497751
Drug: Crizanlizumab 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizanlizumab 7.5 mg/kg
Study: 39498340
Drug: Digoxin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.25 mg every other day) combined with csDMARDs for 6 months
Study: 39499011
Drug: 68 Ga-HBED-CC-exendin-4
Normalized name: Ga-Psma-hbed-CC Ga-68
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68 Ga-HBED-CC-exendin-4
Study: 39499142
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 400 mg twice daily for 6 months
Study: 39499437
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of individual session at baseline and group session 3 months later
Study: 39500299
Drug: Blended cognitive
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended cognitive behavioural intervention (combination of a web-based program and sessions with a psychologist)
Study: 39500883
Drug: JMT103 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: JMT103 (2 mg/kg) administered subcutaneously every four weeks, with loading doses on days 8 and 15.
Study: 39500896
Drug: Vincristine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine treatment
Study: 39501351
Drug: Lurasidone (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (median dosage 37.00 mg/day at baseline, increased to 74.00 mg/day at 3 months)
Study: 39501388
Drug: Tocilizumab (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (280 mg intravenous single dose)
Study: 39501831
Drug: Angong Niuhuang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angong Niuhuang Pills (ANP) 3 g/day for 5 days
Study: 39501831
Drug: Angong Niuhuang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angong Niuhuang Pills (ANP)
Study: 39501831
Drug: Angong Niuhuang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angong Niuhuang Pills (ANP) in patients with large artery atherosclerosis
Study: 39502029
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment effect of PCI versus CABG
Study: 39502066
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K Antagonist
Study: 39502135
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 IU X3/day)
Study: 39503770
Drug: Targeting NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeting NO bioavailability in CD36 deficiency
Study: 39503798
Drug: Pharmacist-guided deprescribing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-guided deprescribing of antihypertensive medications
Study: 39503798
Drug: Family physician-guided
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Family physician-guided treatment adjustments
Study: 39504016
Drug: Olmesartan/Amlodipine single-pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan/Amlodipine single-pill combination (SPC) therapy
Study: 39504023
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of mRNA COVID-19 vaccine and quadrivalent inactivated influenza vaccine (IIV4)
Study: 39504023
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of mRNA COVID-19 vaccine and quadrivalent inactivated influenza vaccine (IIV4)
Study: 39504023
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration
Study: 39504023
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration
Study: 39504025
Drug: Increased nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased nicotine replacement therapy intensity (4-week combination nicotine patch plus nicotine lozenge)
Study: 39504025
Drug: Increased nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased nicotine replacement therapy intensity (2-week nicotine patch)
Study: 39504520
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group (standard-care treatment delayed until intrauterine pregnancy was confirmed)
Study: 39504548
Drug: Remote Patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote Patient Monitoring (RPM+) with digital therapeutics (DTx) solution
Study: 39504548
Drug: Remote Patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote Patient Monitoring (RPM-) without digital therapeutics (DTx) solution
Study: 39505121
Drug: Gamification intervention
Normalized name: Gamifant
DrugBank: Emapalumab (DB14724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gamification intervention informed by behavioral economic concepts; participants receive a wearable fitness tracker and set a goal to increase daily step count by 1,500-3,000 steps from baseline; intervention duration is 6 months.
Study: 39505279
Drug: Peanut oral
Normalized name: Peanut Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut oral immunotherapy (n=95) for 24 months
Study: 39505279
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg peanut (PN-300) for 12 months (n=30)
Study: 39506293
Drug: SPP-continuation (n=24);
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPP-continuation (n=24); SPP in month 1, continuation treatment in month 2
Study: 39506529
Drug: Ponatinib (PON)
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ponatinib (PON) 30 mg/day in chronic phase (CP-CML)
Study: 39506529
Drug: Ponatinib (PON)
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ponatinib (PON) 45 mg/day in accelerated/blastic phase (AP/BP-CML)
Study: 39506647
Drug: Ballet technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ballet technique intervention (one-hour classes twice per week for six weeks)
Study: 39506737
Drug: Combination approach
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination approach
Study: 39507037
Drug: PD-1/PD-L1 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1/PD-L1 inhibitors with baseline bone metastasis (BoM)
Study: 39507037
Drug: PD-1/PD-L1 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1/PD-L1 inhibitors without baseline bone metastasis (BoM)
Study: 39507039
Drug: TQB2450 (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 (1,200 mg) plus anlotinib (8 mg)
Study: 39507039
Drug: TQB2450 (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 (1,200 mg) plus placebo
Study: 39507456
Drug: Vasopressor therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressor therapy
Study: 39507857
Drug: Active Low
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Low Intensity Shockwave Therapy (LiSWT)
Study: 39507860
Drug: Low-intensity shockwave
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity shockwave therapy (LiSWT), treated twice weekly for 3 consecutive weeks with a Storz device.
Study: 39507860
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (control group), patients crossed over at 1 month and were unblinded.
Study: 39508144
Drug: Low-dose intracoronary
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intracoronary adenosine
Study: 39508144
Drug: High-dose intracoronary
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intracoronary adenosine (HDIC)
Study: 39508283
Drug: Previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment for UTI
Study: 39509108
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment (randomization to early treatment)
Study: 39509231
Drug: Sertraline (pharmacotherapy)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (pharmacotherapy)
Study: 39509708
Drug: MAL-ADL-PDT (160mg/g
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAL-ADL-PDT (160mg/g MAL cream)
Study: 39509711
Drug: Xpert HR-CAD4TB
Normalized name: CPERT
DrugBank: Technetium Tc-99m pertechnetate (DB09314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xpert HR-CAD4TB [sequential negative]
Study: 39509711
Drug: CRP-CAD4TB [sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP-CAD4TB [sequential negative]
Study: 39509711
Drug: Xpert HR-CAD4TB
Normalized name: CPERT
DrugBank: Technetium Tc-99m pertechnetate (DB09314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xpert HR-CAD4TB [sequential positive]
Study: 39510247
Drug: Blue light
Normalized name: Ocuvite Blue Light Mini Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue light exposure for 25 minutes daily for 5 or more days
Study: 39510247
Drug: Red light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red light exposure for 25 minutes daily for 5 or more days (placebo)
Study: 39510322
Drug: 5xICS (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5xICS (inhaled corticosteroids)
Study: 39510322
Drug: 1xICS (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1xICS (inhaled corticosteroids)
Study: 39510519
Drug: 12 mm
Normalized name: ReliOn Pen Needle 29g 12 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mm mini-implants
Study: 39510519
Drug: 14 mm
Normalized name: human regenerative tissue mtrx 14 mm TOPICAL SHEET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 mm mini-implants
Study: 39510727
Drug: Iron-containing supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-containing supplements (mainly multivitamins) taken prepregnancy/early pregnancy
Study: 39510727
Drug: Ferritin <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferritin < 60 μg/L
Study: 39510727
Drug: Ferritin <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferritin < 15 μg/L
Study: 39510727
Drug: Ferritin <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferritin < 30 μg/L
Study: 39510727
Drug: sTfR >
Approvals — FDA: no, EMA: no, PMDA: no
Description: sTfR > 4.4 mg/L
Study: 39510727
Drug: TBI <
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TBI < 0 mg/kg
Study: 39510769
Drug: Pharmacogenetic genotype-guided
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetic genotype-guided statin prescription
Study: 39510769
Drug: Standard-of-care statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care statin prescription
Study: 39511164
Drug: benmelstobart (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: benmelstobart (1200 mg) plus anlotinib (10 mg) plus paclitaxel (135 mg) for 4-6 cycles (21-day)
Study: 39511164
Drug: benmelstobart (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: benmelstobart (1200 mg) plus anlotinib (10 mg) plus chemotherapy
Study: 39511203
Drug: EPA and
Normalized name: Norwegian Cod Liver Oil With EPA and DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA and DHA (2.7 g/day)
Study: 39511203
Drug: EPA and
Normalized name: Norwegian Cod Liver Oil With EPA and DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA and DHA (dose-dependent)
Study: 39511476
Drug: Dexmedetomidine (0.2-0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.2-0.7 mcg/kg/h)
Study: 39511611
Drug: Metformin (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2000 mg/d) with standard of care concurrent chemoradiotherapy (cCRT)
Study: 39511611
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care concurrent chemoradiotherapy (cCRT) without metformin
Study: 39511631
Drug: Enhanced microeconomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced microeconomic intervention including 12 weekly educational group sessions, employment-focused mentoring, and an unconditional grant of US $1200.
Study: 39512761
Drug: Quadrivalent standard-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent standard-dose, inactivated influenza vaccine (SD-IIV4)
Study: 39513023
Drug: Subcutaneous alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous alemtuzumab (12 mg/day, total 60 mg)
Study: 39513023
Drug: Intravenous alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous alemtuzumab (12 mg/day, total 36 mg)
Study: 39513186
Drug: SOC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC plus asunercept 400 mg
Study: 39513186
Drug: SOC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC plus asunercept 100 mg
Study: 39513186
Drug: SOC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC plus asunercept 25 mg
Study: 39513267
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous BNP (0.005 µg/kg per minute)
Study: 39513267
Drug: Combination BNP/PDEV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination BNP/PDEV inhibition with sildenafil (25 mg q12 hours) for 48 hours